Julie Jordan, M.D., is Chief Medical Officer. Dr. Jordan brings over 20 years of industry and clinical expertise involving the design and execution of global clinical trials across multiple development areas, including gene therapy and central nervous system disorders. Before joining Neurogene, she was Chief Medical Officer at Homology Medicines, where she was responsible for leading clinical development and operations, leading regulatory interactions and supporting translational research programs for the company’s pipeline of gene therapy and gene editing candidates for rare diseases. She previously held global leadership roles of increasing responsibility at Cerevel Therapeutics, Avanir Pharmaceuticals and Teva Pharmaceutical Industries. Prior to her industry experience, Dr. Jordan was a practicing physician for 10 years and previously served as Clinical Instructor of Medicine at Harvard Medical School and in the Department of Medicine at Massachusetts General Hospital (MGH). She holds an A.B. in Biology from Harvard College and an M.D. from Harvard Medical School and completed her residency in Internal Medicine at MGH, Harvard Medical School.